Lawmakers Hear Evidence of Gray Market in Shortage Drugs

Experts discuss personalized myasthenia gravis treatment, emphasizing patient education and engagement for optimal care and advocacy in managing this variable disease.

Medbridge is working to refine remote therapeutic monitoring, or RTM, to transform physical therapy and enhance patient care.

Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar competition in the US.

Discover how the Hearing Loss Association of America advocates for hearing loss awareness and hearing health integration through a dialogue with Barbara Kelley, executive director.

The FDA announced draft guidance to remove clinical efficacy studies for biosimilars and also issued the position that all biosimilars in the US should be interchangeable.

Premiums for coverage on the ACA marketplaces are set to jump by an average of 26% next year, even before the expiration of subsidies is factored in.